Pfizer Sues To Block Generic Caduet Until 2016

Law360, New York (March 25, 2008, 12:00 AM EDT) -- In a move that could stop Ranbaxy Laboratories Ltd. from marketing a generic version of the hybrid blood pressure and cholesterol drug Caduet until 2016, Pfizer Inc. lodged a declaratory judgment suit on Monday claiming that Ranbaxy's proposed generic would infringe two patents related to atorvastatin.

Pfizer filed its complaint in the U.S. District Court for the District of Delaware, seeking a judgment that Ranbaxy's copycat Caduet would infringe two patents Pfizer says are valid through July 16, 2016. The suit seeks injunctive relief barring Ranbaxy...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.